Copyright © Inderes 2011 - present. All rights reserved.
Press release

Invitation to BICO’s Capital Markets Day 2024

BICO Group

On September 17, 2024, BICO Group AB (publ) invites you to our Capital Markets Day with a focus on the Group’s strategic direction. BICO’s President and CEO Maria Forss will together with the Executive Management present the company's updated strategy, BICO 2.0. In addition, a deep dive within lab automation will be presented. The Capital Markets Day ends with a Q&A.

Agenda for BICO’s Capital Markets Day 2024

  • BICO strategy 2.0 – BICO’s Executive Management
  • Lab automation and Deepcure – Ryan Bernhardt, CEO Biosero and Derrick Miyao, VP Molecular Foundry, Deepcure
  • Q&A moderated by Ulrik Trattner, Research analyst, Carnegie
  • Demonstration of BICO’s innovative product portfolio and lab automation (only for attendees in Gothenburg)

Location and registration: BICO’s Capital Markets Day is a hybrid event. You can either participate by attendance physically at BICO’s head office, Långfilsgatan 9, in Gothenburg or digitally. Attendance in Gothenburg is primarily intended for institutional shareholders, analysts and financial advisors.

If you wish to participate physically, you are asked to register by notifying your attendance to BICO Investor Relations, ir@bico.com, no later than Thursday September 12, 2024.

If you wish to participate digitally, please register to the event via this link: https://ir.financialhearings.com/bico-capital-markets-day-2024/register. The Capital Markets Day will be broadcast live online between 1-4pm CEST. A recording of the Capital Markets Day will be available on-demand on www.bico.com after the event.

Date: Tuesday September 17, 2024
Time: Presentations between 1-4pm CEST (both online and for attendees in Gothenburg) and demo and exhibition between 4-6pm CEST (only for attendees in Gothenburg).

All presentations will be held in English.

For further information, please contact:
Maria Forss, President & CEO, BICO Group AB
Phone: EA Isabella Lundin +46 73 515 99 64
E-mail: mf@bico.com

Jacob Thordenberg, Chief Financial Officer, BICO Group AB
Phone: +46 73 534 88 84
E-mail: jt@bico.com

BICO Investor Relations
Phone: +46 735 46 57 77
E-mail: ir@bico.com

The information was submitted for publication, through the agency of the contact person set out above, on August 15, 2024 at 7.00am CEST.

About BICO
BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 46,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 12,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction of the world’s organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments
Invitation to BICO’s Capital Markets Day 2024